These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 32114747)

  • 21. Is a "Cytokine Storm" Relevant to COVID-19?
    Sinha P; Matthay MA; Calfee CS
    JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883
    [No Abstract]   [Full Text] [Related]  

  • 22. The resurgence of convalescent plasma therapy.
    The Lancet Haematology
    Lancet Haematol; 2020 May; 7(5):e353. PubMed ID: 32359447
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunotherapeutic approaches to curtail COVID-19.
    Owji H; Negahdaripour M; Hajighahramani N
    Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive antibody therapy in COVID-19.
    Abraham J
    Nat Rev Immunol; 2020 Jul; 20(7):401-403. PubMed ID: 32533109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The possible of immunotherapy for COVID-19: A systematic review.
    AminJafari A; Ghasemi S
    Int Immunopharmacol; 2020 Jun; 83():106455. PubMed ID: 32272396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment.
    Ouyang J; Isnard S; Lin J; Fombuena B; Peng X; Routy JP; Chen Y
    Front Immunol; 2020; 11():570063. PubMed ID: 33072111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients.
    Lanza F; Seghatchian J
    Br J Haematol; 2020 Jul; 190(1):e27-e29. PubMed ID: 32407543
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
    Mustafa MI; Abdelmoneim AH; Mahmoud EM; Makhawi AM
    Mediators Inflamm; 2020; 2020():8198963. PubMed ID: 33029105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The convalescent sera option for containing COVID-19.
    Casadevall A; Pirofski LA
    J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives.
    Tamburello A; Marando M
    Swiss Med Wkly; 2020 Apr; 150():w20264. PubMed ID: 32343358
    [No Abstract]   [Full Text] [Related]  

  • 31. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
    Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
    [No Abstract]   [Full Text] [Related]  

  • 32. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
    Morabito CJ; Gangadharan B
    Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
    [No Abstract]   [Full Text] [Related]  

  • 33. Antibody-based therapies for COVID-19: Can Europe move faster?
    Kazatchkine MD; Goldman M; Vincent JL
    PLoS Med; 2020 May; 17(5):e1003127. PubMed ID: 32369479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Ranger A; Haji R; Kaczmarski R; Danga A
    Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma Therapies and Parabiosis in the COVID-19 Era.
    Calvani R; Picca A; Landi F; Marzetti E
    J Am Med Dir Assoc; 2020 Jul; 21(7):994-995. PubMed ID: 32674834
    [No Abstract]   [Full Text] [Related]  

  • 36. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.
    Peng H; Gong T; Huang X; Sun X; Luo H; Wang W; Luo J; Luo B; Chen Y; Wang X; Long H; Mei H; Li C; Dai Y; Li H
    Stem Cell Res Ther; 2020 Jul; 11(1):291. PubMed ID: 32678017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
    Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
    Front Immunol; 2020; 11():1648. PubMed ID: 32754159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management.
    Verma A; Adhikary A; Woloschak G; Dwarakanath BS; Papineni RVL
    Int J Radiat Biol; 2020 Nov; 96(11):1323-1328. PubMed ID: 32910699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19: Proposing a Ketone-Based Metabolic Therapy as a Treatment to Blunt the Cytokine Storm.
    Bradshaw PC; Seeds WA; Miller AC; Mahajan VR; Curtis WM
    Oxid Med Cell Longev; 2020; 2020():6401341. PubMed ID: 33014275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.